To better understand this scenario, Anderson et al. designed a custom CRISPR/Cas9 library to map the landscape of druggable pathways cooperating with inhibitors of the key KRAS effectors (MEK, ERK and PI3K) in different types of KRAS-driven cell line cancer models [86]. This evidence concerns the gene KRAS and cancer.